EP1677788A1 - Alkynes iii - Google Patents

Alkynes iii

Info

Publication number
EP1677788A1
EP1677788A1 EP04795637A EP04795637A EP1677788A1 EP 1677788 A1 EP1677788 A1 EP 1677788A1 EP 04795637 A EP04795637 A EP 04795637A EP 04795637 A EP04795637 A EP 04795637A EP 1677788 A1 EP1677788 A1 EP 1677788A1
Authority
EP
European Patent Office
Prior art keywords
prop
methyl
hydrogen
pyridine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04795637A
Other languages
German (de)
French (fr)
Inventor
Peter AstraZeneca R & D Molndal BACH
Udo AstraZeneca R & D Molndal BAUER
Karolina AstraZeneca R & D Molndal NILSSON
Andreas AstraZeneca R & D Molndal WALLBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Shire NPS Pharmaceuticals Inc
Original Assignee
AstraZeneca AB
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, NPS Pharmaceuticals Inc filed Critical AstraZeneca AB
Publication of EP1677788A1 publication Critical patent/EP1677788A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Definitions

  • the present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
  • mGluR metabotropic glutamate receptors
  • CNS central nervous system
  • Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity.
  • Group I consists of mGluRl and mGluR5. These receptors activate phospholipase C and increase neuronal excitability.
  • Group II consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluR.6, mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission.
  • the lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".
  • Gastro-esophageal reflux disease is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.
  • TLESRs transient lower esophageal sphincter relaxations
  • the problem underlying the present invention was to find new compounds useful in the treatment of GERD.
  • WO 01/16121 Al discloses a compound A-L-B, where A is a 5-, 6- o rr 77--nmembered heterocycle
  • L i an alkenylene, alkynylene or azo
  • B is a hydrocarbyl; cyclohydrocarbyl; heterocycle (optionally containing one or more double bonds); or aryl.
  • WO 99/02497 A2 discloses compounds of the formula
  • X may be an alkenylene or an alkynylene bonded via vicinal unsaturated carbon atoms, or an azo group; and R 5 may be an aromatic or heteroaromatic group.
  • the present invention is directed to novel compounds according to the general formula I:
  • R 1 is selected from hydrogen, - alkyl, C 3 -C 6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C ! -C alkyl;
  • R is selected from hydrogen and Ci-C 4 alkyl
  • R is selected from hydrogen, C 1 -C 4 alkyl, F, CF 3 , CHF and CH 2 F;
  • R 4 is selected from hydrogen, F, CF 3 , CHF 2 , CH 2 F and CH 3 ;
  • R 5 is selected from hydrogen and F; R is selected from hydrogen and F;
  • Y 1 is selected from hydrogen; halogen; nitrile; -C 4 alkoxy; C 1 -C 4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; benzyloxy; nitro in the meta or para position; and C 1 -C 4 alkyl ester;
  • Y 2 is selected from hydrogen; halogen; nitrile; C 1 -C 4 alkoxy; C 1 -C 4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and
  • Y 3 is selected from hydrogen; halogen; nitrile; C 1 -C 4 alkoxy; C 1 -C 4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and
  • C 1 -C 4 alkyl ester or Y 1 and Y 2 may form an aromatic or non-aromatic ring, optionally substituted by halogen, nitrile, C1-C4 alkoxy, C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom, benzyloxy or C 1 -C 4 alkyl ester; with the proviso that when Y is hydrogen, Y is selected from halogen, nitrile, C 1 -C 4 alkoxy, and C 1 -C4 alkyl; as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.
  • Halogen is chloro, fluoro, bromo or iodo.
  • C 1 -C 4 alkyl is a straight or branched alkyl group, each independently containing 1, 2, 3 or 4 carbon atoms, for example methyl, ethyl, n-propyl, n-butyl or isopropyl.
  • the alkyl groups may contain one or more heteroatoms selected from O, N and S. Examples of such groups are methyl-ethylether, methyl-ethylamine and methyl- thiomethyl.
  • Cycloalkyl is a cyclic alkyl, each independently containing 3, 4, 5 or 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • C 1 -C 4 alkoxy is an alkoxy group containing 1, 2, 3 or 4 carbon atoms, such as methoxy, ethoxy, n-propoxy, n-butoxy or isopropoxy.
  • aryl means aromatic rings with 6-14 carbon atoms including both single rings and poly cyclic compounds, such as phenyl, benzyl or naphtyl.
  • heteroaryl as used herein means aromatic rings with 5-14 carbon atoms, including both single rings and polycyclic compounds, such as imidazopyridine, in which one or several of the ring atoms is either oxygen, nitrogen or sulphur, such as furanyl or thiophenyl.
  • salts of the compound of formula I are also within the scope of the present invention.
  • Such salts are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.
  • novel compounds according to the present invention are useful in therapy.
  • said compounds are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for treatment or prevention of gastro- esophageal reflux disorder (GERD).
  • TLESRs transient lower esophageal sphincter relaxations
  • GERD gastro- esophageal reflux disorder
  • the compounds according to the present invention are useful for the prevention of reflux, treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.
  • a further aspect of the invention is the use of a compound according to formula I, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment or prevention of GERD, for the prevention of reflux, for the treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.
  • a further aspect of the invention is the use of a compound according to formula I for the manufacture of a medicament for the treatment or prevention of functional gastrointestinal disorders, such as functional dyspepsia (FD).
  • FD functional dyspepsia
  • Yet another aspect of the invention is the use of a compound according to formula I for the manufacture of a medicament for the treatment or prevention of irritable bowel syndrome (IBS), such as constipation predominant IBS, diarrhea predominant IBS or alternating bowel movement predominant IBS.
  • IBS irritable bowel syndrome
  • Still a further aspect of the invention is a method for the treatment of any one of the conditions mentioned above, whereby a pharmaceutically effective amount of a compound according to formula I above, is administered to a subject suffering from said condition(s).
  • the compounds of formula I are useful for the treatment and/or prevention of acute and chronic neurological and psychiatric disorders, anxiety and chronic and acute pain disorders.
  • said compounds are useful for the prevention and/or treatment of pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatoid diseases, low back pain, post-operative pain and pain associated with various conditions including cancer, angina, renal or billiary colic, menstruation, migraine and gout.
  • isomers is herein defined as compounds of formula I, which differ by the position of their functional groups and/or orientation.
  • orientation is meant stereoisomers, diastereoisomers, regioisomers and enantiomers.
  • isoforms as used herein is defined as compounds of formula I which differ by their crystal lattice, such as crystalline compounds and amorphous compounds.
  • TLESR transient lower esophageal sphincter relaxations
  • the wording "reflux” is defined herein as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.
  • the wording "GERD”, gastro-esophageal reflux disease, is defined herein in accordance with van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Bailliere 's Clin. Gastroenterol 14, pp. 759-774.
  • the mesylate of the primary alcohol is isolated and characterised, while that of the secondary alcohols are made in situ. Finally, the respective mesylate is reacted with the alcohol. This can either be done by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this solution to generate product (I) (Scheme 1).
  • a base such as triethyl amine
  • the product (I) is formed by an alternative route (scheme 2): first the aryl bromide A is coupled with ethynyl(trimethyl)silane F via Sonogashira coupling at 60 °C in triethyl amine to give product G. Deprotection of G at room temperature with potassium carbonate in methanol/DCM gives terminal alkyne H, which is deprotonated with lithium bis(trimethylsily ⁇ )amide in THF at - 78 °C.
  • the mesylate J is formed in situ with methanesulfonyl chloride and triethyl amine, either at room temperature or with cooling.
  • the reaction of the alcohol with this mesylate is either performed by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this solution to form product (I).
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , Y 1 , Y 2 and Y 3 are defined as for the compounds of formula I above.
  • DCM is dried over 3A molecular sieves.
  • THF was distilled from Na benzophenone just prior to use. All reactions are run under a nitrogen atmosphere. All glassware is dried in at 150 °C for at least two hours prior to its use. Phase separators from International Sorbent Technology (1ST) are used. Purification by chromatography is done either on silica gel 60 (0.040-0.063 mm), or by reverse phase chromatography with a C8 column. All NMR spectra are measured in 5-chloroform.
  • 2-bromo-6-methylpyridine is commercially available from Aldrich, (PPh3) 2 PdCl 2 from Avacado, Pd (OAc) 2 from Aldrich and Cul from Fluka. If not stated otherwise, the chemicals used are commercially available and are used as such without further purification.
  • the compounds of formula I are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations.
  • the compounds of formula I are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant.
  • the carrier may be in the form of a solid, semi-solid or liquid diluent.
  • the compound of formula I to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes.
  • Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules.
  • Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
  • Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
  • Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g.
  • liquid preparations containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol.
  • liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent.
  • Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
  • Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
  • the compounds of formula I may be administered once or twice daily, depending on the severity of the patient's condition.
  • a typical daily dose of the compounds of formula I is from 0.1 - 10 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.
  • the compound was prepared according to method A using methanesulfonic acid 1-methyl- 3-(6-methyl-pyridin-2-yl)-prop-2-ynyl ester and 3-chlorophenol.
  • Phosphate buffer (10 mL, 0.2 M, pH 7) was added and the water phase was extracted with
  • reaction mixture was added to water (10 mL) and the pH was adjusted to 6-7 with
  • the properties of the compounds of the invention can be analyzed using standard assays for pharmacological activity.
  • glutamate receptor assays are well known in the art as described in for example Aramori et al, Neuron 8:151 (1992), Tanabe et al., Neuron ⁇ :169 (1992), Miller et al, J Neuroscience 15: 6103 (1995), Balazs, et al, J.
  • the compounds of the invention can be studied by means of an assay (FLIPR) that measures the mobilization of intracellular calcium, [Ca 2+ ]j in cells expressing mGluR5 or another assay (IP3) that measures inositol phosphate turnover.
  • FLIPR assay
  • IP3 another assay
  • a 40 ⁇ l addition from the antagonist plate was followed by a 50 ⁇ L addition from the agonist plate.
  • a 90 second interval separates the antagonist and agonist additions.
  • the fluorescence signal is sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals immediately after each of the two additions. Responses are measured as the difference between the peak height of the response to agonist, less the background fluorescence within the sample period.
  • IC5 0 determinations are made using a linear least squares fitting program.
  • mGluR5d An additional functional assay for mGluR5d is described in WO97/05252 and is based on phosphatidylinositol turnover. Receptor activation stimulates phospholipase C activity and leads to increased formation of inositol l,4,5,triphosphate (IP3).
  • IP3 inositol l,4,5,triphosphate
  • GHEK stably expressing the human mGluR5d are seeded onto 24 well poly-L-lysine coated plates at 40 x 10 4 cells /well in media containing 1 ⁇ Ci/well [3H] myo-inositol.
  • HEPES buffered saline 146 mM NaCl, 4.2 mM KC1, 0.5 mM MgCl 2 , 0.1% glucose, 20 mM HEPES, pH 7.4
  • HEPES buffered saline 146 mM NaCl, 4.2 mM KC1, 0.5 mM MgCl 2 , 0.1% glucose, 20 mM HEPES, pH 7.4
  • 1 unit ml glutamate pyruvate transaminase and 2 mM pyruvate were washed once in HEPES buffered saline and pre-incubated for 10 min in HEPES buffered saline containing 10 mM LiCl.
  • Inositol phosphate separation was done by first eluting glycero phosphatidyl inositol with ⁇ ml 30 mM ammonium formate. Next, total inositol phosphates is eluted with ⁇ ml 700 mM ammonium formate / 100 mM formic acid and collected in scintillation vials. This eluate is then mixed with ⁇ ml of scintillant and [3H] inositol incorporation is determined by scintillation counting. The dpm counts from the duplicate samples are plotted and IC 50 determinations are generated using a linear least squares fitting program.
  • the compounds are active in the assay above with IC 50 values less than 10 000 nM.
  • the IC 5 o value is less than 1 ⁇ M.
  • the IC 50 value is less than 100 nM.
  • a multilumen sleeve/sidehole assembly (Dentsleeve, Sydney, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures.
  • the assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Sydney, South Australia).
  • An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.
  • placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein.
  • a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg.
  • the infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until an intragastric pressure of 10+1 mmHg is obtained.
  • the pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach.
  • the experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs.
  • TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s.
  • the relaxation should not be preceded by a pharyngeal signal 2s before its onset in which case the relaxation is classified as swallow- induced.
  • the pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to novel compounds of formula 1, to a process, for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds. The novel compounds are useful in therapy, and in particular for the treatment 5 of gastroesophageal reflux disease (GERD).

Description

ALKYNES III
Field of the invention
The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
Background of the invention
The metabotropic glutamate receptors (mGluR) are G-protein coupled receptors that are involved in the regulation and activity of many synapses in the central nervous system (CNS). Eight metabotropic glutamate receptor subtypes have been identified and are subdivided into three groups based on sequence similarity. Group I consists of mGluRl and mGluR5. These receptors activate phospholipase C and increase neuronal excitability. Group II, consisting of mGluR2 and mGluR3 as well as group III, consisting of mGluR4, mGluR.6, mGluR7 and mGluR8 are capable of inhibiting adenylyl cyclase activity and reduce synaptic transmission. Several of the receptors also exist in various isoforms, occurring by alternative splicing (Chen, C-Yet al, Journal of Physiology (2002), 538.3, pp. 773-786; Pin, J-P et al, European Journal of Pharmacology (1999), 375, pp. 277-294; Brάuner-Osborne, H et al. Journal of Medicinal Chemistry (2000), 43, pp. 2609-2645; Schoepp, D.D, Jane D.E. Monn J.A. Neuropharmacology (1999), 38, pp. 1431-1476).
The lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".
Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.
The problem underlying the present invention was to find new compounds useful in the treatment of GERD.
WO 01/16121 Al discloses a compound A-L-B, where A is a 5-, 6- o rr 77--nmembered heterocycle
L i an alkenylene, alkynylene or azo; and
B is a hydrocarbyl; cyclohydrocarbyl; heterocycle (optionally containing one or more double bonds); or aryl. These compounds have been described as being useful in inter alia cerebral ischemia, chronic neurodegeneration, psychiatric disorders, epilepsy and diseases of the pulmonary system as well as the cardiovascular system.
WO 99/02497 A2 discloses compounds of the formula
wherein X may be an alkenylene or an alkynylene bonded via vicinal unsaturated carbon atoms, or an azo group; and R5 may be an aromatic or heteroaromatic group. These compounds have been described as being useful in inter alia epilepsy, cerebral ischemia and Alzheimer's disease. Outline of the invention
The present invention is directed to novel compounds according to the general formula I:
wherein
R1 is selected from hydrogen, - alkyl, C3-C6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C!-C alkyl;
R is selected from hydrogen and Ci-C4 alkyl;
R is selected from hydrogen, C1-C4 alkyl, F, CF3, CHF and CH2F;
R4 is selected from hydrogen, F, CF3, CHF2, CH2F and CH3;
R5 is selected from hydrogen and F; R is selected from hydrogen and F;
Y1 is selected from hydrogen; halogen; nitrile; -C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; benzyloxy; nitro in the meta or para position; and C1-C4 alkyl ester;
Y2 is selected from hydrogen; halogen; nitrile; C1-C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and
C1-C4 alkyl ester;
Y3 is selected from hydrogen; halogen; nitrile; C1-C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and
C1-C4 alkyl ester; or Y1 and Y2 may form an aromatic or non-aromatic ring, optionally substituted by halogen, nitrile, C1-C4 alkoxy, C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom, benzyloxy or C1-C4 alkyl ester; with the proviso that when Y is hydrogen, Y is selected from halogen, nitrile, C1-C4 alkoxy, and C1-C4 alkyl; as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.
The general terms used in the definition of formula I have the following meanings:
Halogen is chloro, fluoro, bromo or iodo.
C1-C4 alkyl is a straight or branched alkyl group, each independently containing 1, 2, 3 or 4 carbon atoms, for example methyl, ethyl, n-propyl, n-butyl or isopropyl. In one embodiment, the alkyl groups may contain one or more heteroatoms selected from O, N and S. Examples of such groups are methyl-ethylether, methyl-ethylamine and methyl- thiomethyl.
Cycloalkyl is a cyclic alkyl, each independently containing 3, 4, 5 or 6 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
C1-C4 alkoxy is an alkoxy group containing 1, 2, 3 or 4 carbon atoms, such as methoxy, ethoxy, n-propoxy, n-butoxy or isopropoxy.
The herein used term aryl means aromatic rings with 6-14 carbon atoms including both single rings and poly cyclic compounds, such as phenyl, benzyl or naphtyl.
The term heteroaryl as used herein means aromatic rings with 5-14 carbon atoms, including both single rings and polycyclic compounds, such as imidazopyridine, in which one or several of the ring atoms is either oxygen, nitrogen or sulphur, such as furanyl or thiophenyl.
Within the scope of the invention are also pharmaceutically acceptable salts of the compounds of formula I as well as isomers, hydrates and isoforms thereof.
Pharmaceutically acceptable salts of the compound of formula I are also within the scope of the present invention. Such salts are for example salts formed with mineral acids such as hydrochloric acid; alkali metal salts such as sodium or potassium salts; or alkaline earth metal salts such as calcium or magnesium salts.
The novel compounds according to the present invention are useful in therapy. In one aspect of the invention said compounds are useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for treatment or prevention of gastro- esophageal reflux disorder (GERD). In further embodiments, the compounds according to the present invention are useful for the prevention of reflux, treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.
A further aspect of the invention is the use of a compound according to formula I, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment or prevention of GERD, for the prevention of reflux, for the treatment or prevention of regurgitation, treatment or prevention of asthma, treatment or prevention of laryngitis, treatment or prevention of lung disease and for the management of failure to thrive.
A further aspect of the invention is the use of a compound according to formula I for the manufacture of a medicament for the treatment or prevention of functional gastrointestinal disorders, such as functional dyspepsia (FD). Yet another aspect of the invention is the use of a compound according to formula I for the manufacture of a medicament for the treatment or prevention of irritable bowel syndrome (IBS), such as constipation predominant IBS, diarrhea predominant IBS or alternating bowel movement predominant IBS.
Still a further aspect of the invention is a method for the treatment of any one of the conditions mentioned above, whereby a pharmaceutically effective amount of a compound according to formula I above, is administered to a subject suffering from said condition(s).
In one aspect of the invention, the compounds of formula I are useful for the treatment and/or prevention of acute and chronic neurological and psychiatric disorders, anxiety and chronic and acute pain disorders. In a further aspect, said compounds are useful for the prevention and/or treatment of pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatoid diseases, low back pain, post-operative pain and pain associated with various conditions including cancer, angina, renal or billiary colic, menstruation, migraine and gout.
The term "isomers" is herein defined as compounds of formula I, which differ by the position of their functional groups and/or orientation. By "orientation" is meant stereoisomers, diastereoisomers, regioisomers and enantiomers.
The term "isoforms" as used herein is defined as compounds of formula I which differ by their crystal lattice, such as crystalline compounds and amorphous compounds.
The wording "TLESR", transient lower esophageal sphincter relaxations, is herein defined in accordance with Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J., 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610.
The wording "reflux" is defined herein as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times. The wording "GERD", gastro-esophageal reflux disease, is defined herein in accordance with van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Bailliere 's Clin. Gastroenterol 14, pp. 759-774.
Methods of preparation
First, a Sonogashira coupling (Tetrahedron Letters 1975, 50, 4467, S. Thorand, N. Krause J Org. Chem., 1998, 63, 8551-8553, M. Erdelyi, A. Gogoll, J. Org. Chem., 2001, 66, 4165-4169) of the aryl bromide A and the alcohol B in the presence of a base such as triethyl amine at room temperature to 60 °C gives the alcohol C which is then converted into the mesylate D with methanesulfonyl chloride in triethyl amine at about 0 to -20 °C. The mesylate of the primary alcohol is isolated and characterised, while that of the secondary alcohols are made in situ. Finally, the respective mesylate is reacted with the alcohol. This can either be done by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this solution to generate product (I) (Scheme 1).
SCHEME 1
In those cases where the alcohol B is not commercially available with a desired Regroup, the product (I) is formed by an alternative route (scheme 2): first the aryl bromide A is coupled with ethynyl(trimethyl)silane F via Sonogashira coupling at 60 °C in triethyl amine to give product G. Deprotection of G at room temperature with potassium carbonate in methanol/DCM gives terminal alkyne H, which is deprotonated with lithium bis(trimethylsilyι)amide in THF at - 78 °C. At - 78 °C an aldehyde or a ketone is added and the reaction mixture is allowed to reach room temperature and kept at that temperature for the appropriate time to form the alcohol I. Having isolated I, the mesylate J is formed in situ with methanesulfonyl chloride and triethyl amine, either at room temperature or with cooling. The reaction of the alcohol with this mesylate is either performed by adding the alcohol and a base such as triethyl amine to the mesylate in a solvent such as DCM or by pre-reacting the alcohol with a base such as sodium hydride in a solvent such as THF and subsequently adding the mesylate to this solution to form product (I). SCHEME 2 Variations of compounds of formula I are investigated by first forming an aryl prop-2-yn- 1-yl ether M by reaction of a phenol K with 3-bromoprop-l-yne [= propargyl bromide] L in the presence of a base such as potassium carbonate in e.g. acetone at temperatures from room temperature to 60 °C for the appropriate time (Scheme 3). The propargyl ether M is then reacted in a Sonogashira coupling with an aryl bromide in the presence of a base such as triethyl amine at temperatures from room temperature to 60 °C for the appropriate time.
K then 60 °C/17h (PPh3)2PdCI2, Cul, NEt3 60 °C/ 2 ArX, X=Br or I
SCHEME 3 In the schemes 1, 2 and 3 above, R1, R2, R3, R4, R5, R6, Y1, Y2 and Y3 are defined as for the compounds of formula I above.
Experimental details
DCM is dried over 3A molecular sieves. THF was distilled from Na benzophenone just prior to use. All reactions are run under a nitrogen atmosphere. All glassware is dried in at 150 °C for at least two hours prior to its use. Phase separators from International Sorbent Technology (1ST) are used. Purification by chromatography is done either on silica gel 60 (0.040-0.063 mm), or by reverse phase chromatography with a C8 column. All NMR spectra are measured in 5-chloroform.
2-bromo-6-methylpyridine is commercially available from Aldrich, (PPh3)2PdCl2 from Avacado, Pd (OAc)2 from Aldrich and Cul from Fluka. If not stated otherwise, the chemicals used are commercially available and are used as such without further purification. Pharmaceutical formulations
For clinical use, the compounds of formula I are in accordance with the present invention suitably formulated into pharmaceutical formulations for oral administration. Also rectal, parenteral or any other route of administration may be contemplated to the skilled man in the art of formulations. Thus, the compounds of formula I are formulated with at least one pharmaceutically and pharmacologically acceptable carrier or adjuvant. The carrier may be in the form of a solid, semi-solid or liquid diluent.
In the preparation of oral pharmaceutical formulations in accordance with the invention, the compound of formula I to be formulated is mixed with solid, powdered ingredients such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives, gelatin, or another suitable ingredient, as well as with disintegrating agents and lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethylene glycol waxes. The mixture is then processed into granules or compressed into tablets.
Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound or compounds of the invention, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Hard gelatine capsules may contain the active compound in combination with solid powdered ingredients such as lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives or gelatine.
Dosage units for rectal administration may be prepared (i) in the form of suppositories which contain the active substance(s) mixed with a neutral fat base; (ii) in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil, or other suitable vehicle for gelatine rectal capsules; (iii) in the form of a ready-made micro enema; or (iv) in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration. Liquid preparations for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions, containing the active compound and the remainder of the formulation consisting of sugar or sugar alcohols, and a mixture of ethanol, water, glycerol, propylene glycol and polyethylene glycol. If desired, such liquid preparations may contain colouring agents, flavouring agents, saccharine and carboxymethyl cellulose or other thickening agent. Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use.
Solutions for parenteral administration may be prepared as a solution of a compound of the invention in a pharmaceutically acceptable solvent. These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. Solutions for parenteral administration may also be prepared as a dry preparation to be reconstituted with a suitable solvent extemporaneously before use.
In one aspect of the present invention, the compounds of formula I may be administered once or twice daily, depending on the severity of the patient's condition.
A typical daily dose of the compounds of formula I is from 0.1 - 10 mg per kg body weight of the subject to be treated, but this will depend on various factors such as the route of administration, the age and weight of the patient as well as of severity of the patient's condition.
Examples Method K
Example 1 Preparation of 3-(prop-2-yn-l-yloxy)benzene (compound 21):
~^°-o (21)
Potassium carbonate (1.382 g, 0.1 mol) was added to a solution of phenol (0.941 g, 0.01 mmol, 1.0 eq.) in acetone (15 mL) at 0 °C. 3-bromoprop-l-yne (1.19 g, 0.89 mL, 0.01 mol,
1.0 eq.) was added. The solution was allowed to reach room temperature and then heated at
60 °C for 17h. After cooling, the solvent was evaporated.
Water (15 mL) was added and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with water (1 x 15 mL), brine (1 x 15 mL), dried with magnesium sulphate and evaporated. This gave 1.026 g (78 %) of product.
TLC: Rf (heptane/EtOAc 2:1) = 0.67.
1H NMR (300 MHz): 7.32-7.24 (m, 2H), 7.02-6.92 (m, 3H), 4.64 (d, J = 2.4 Hz, 2H), 2.48
(t, J = 2.4 Hz, 1H).
13C NMR (75 MHz): 157.6, 129.8, 121.7, 115.1, 78.9, 75.7, 56.0.
Example 2
Preparation of l-methoxy-3-(prop-2-vn-l-yloxy)benzene (compound 22): according to method K above, with 3-methoxyphenol as starting material.
Yield: 99 %. 1H NMR (500 MHz): 7.20-7.14 (m 2H), 6.57-6.51 (m, 3H), 4.63 (d, J = 2.3 Hz, 2H), 3.74
(s, 3H), 2.51 (t, J = 2.4 Hz, IH).
13C NMR (125 MHz): 160.8, 158.8, 129.9, 107.2, 106.9, 101.5, 78.6, 75.6, 55.8, 55.2.
Example 3
Preparation of 2-methyl-6-(3-phenoxyprop-l-vn-l-yl pyridine (compound 23):
To 2-bromo-6-methylpyridine (1.055 g, 6.13 mmol) was added 3-(prop-2-yn-l- yloxy)benzene (0.851 g, 6.44 mmol, 1.10 eq.), followed by (PPh3)2PdCl2 (0.129 g, 0.18 mmol, 0.03 eq.), Cul (0.035 g, 0.18 mmol, 0.03 eq.) and triethylamine (3.50 mL). The mixture was heated under nitrogen at 60 °C for 2h. Phophate buffer (10 mL, 0.2 M, pH 7), was added and the water phase was extracted with DCM (3 x 10 mL). The combined organic phases were dried with magnesium sulphate, evaporated and then filtered through a Si-plug, 1 g, while rinsing with diethyl ether/pentane 1:1, ca. 25 mL. This gave 1.491g after evaporation.
Flash chromatography on Si-gel with heptane/AcOEt, first 9:1, then 3:1, as eluent gave 0.908 g compound.
1H NMR (500 MHz): 7.42 (t, J = 7.8 Hz, IH), 7.27 (t, J = 7.8, 2H), 7.17 (d, J = 7.7 Hz,
IH), 7.01 (m, 3H), 6.95 (t, J = 7.7 Hz, IH), 4,88 (s, 2H), 2.94 (s, 3H).
13C NMR (125 MHz): 158.2, 157.1, 140.9, 135.8, 128.9, 123.7, 122.4, 120.8, 114.2, 85.8,
83.1, 55.7, 23.8. Example 4
Preparation of 2- 3-(3-methoxyphenoxy^prop-l-yn-l-yn-6-methylpyridine (compound 24):
To NaH (0.038 g, 95 % purity, 1.50 mmol, 5.0 eq.) in THF (1 mL) was added 1-methoxy- 3-(prop-2-yn-l-yloxy)benzene (0.037 g, 0.30 mmol, 1.0 eq.) in THF (1 mL) at 0 °C under nitrogen. The mixture was stirred for 10 min. at room temperature. Then, 3-(6- methylpyridin-2-yl)prop-2-yn-l-yl methanesulfonate (0.068 g, 0.30 mmol) in THF (1 mL) was added at 0 °C. The mixture was stirred at room temperature over night (18 h). The mixture was poured onto water (10 mL) and the water phase was extracted with Et2O (2 x 10 mL) and then DCM (2 x 10 mL). The combined organic phases were dried with sodium sulphate and evaporated. This gave 0.041 g crude product which was then purified by reverse phase chromatography. This gave 0.009 g (yield: 12 %) product.
1H NMR (300 MHz): 7.52 (t, J = 7.8 Hz, IH), 7.25 [m (under CDCl3-signal), IH), 7.20 (t, J = 8.2 Hz, IH), 7.10 (d, J = 7.8 Hz, IH), 6.66-6-53 (m, 3H), 4.91 (s, 2H), 3.79 (s, 3H), 2.55 (s, 3H).
Example 5 Preparation of 2-("3-(3-methoxyphenoxy)prop-l-vn-l-yl]pyridine (compound 25): prepared according to example 3 with 2-bromopyridine and l-methoxy-3-(prop-2-yn-l- yloxy)benzene as starting materials.
Example 6, Method A
Preparation of 2-Methyl-6- (3-ρ-tolyloχy-prop-l-ynylVpyridine
To a stirred mixture of 4-methyl-phenol (19mg, O.lSmmol) and K2CO3 (31mg, 0.225mmol) in acetone (0.3ml), methanesulfonic acid 3-(6-methyl-pyridin-2-yl)-prop-2- ynyl ester (34mg, 0.15mmol) dissolved in acetone (0.2ml) was added at room temperature. The mixture was stirred at 60°C for 18h. Since all solvent had evaporated but the reaction was not completed, dimethylformamide (0.5ml) was added and the reaction was stirred at 60°C for another 20h. The solid salt was filtered off and the filtrate was purified by HPLC: Waters FractionLynxsystem with UV, ELSD and MS. Column: Ace C8 5μ 100 mm x 21,2 mm id, mobile phase A: 95% acetonitrile, mobile phase B: 5% acetonitrile + 95% 0,1 M NH4OAc Gradient: From 100% B to 100% A in 10 minutes, Flow: 25 ml/min UV: 254 nm. The title compound, O.OlOg (yield 28%) was isolated. M+H: 238.1
Example 7 Preparation of 2-[3-(3-chlorophenoxy)but-l-yn-l-yl]-6-methylpyridine
The compound was prepared according to method A using methanesulfonic acid 1-methyl- 3-(6-methyl-pyridin-2-yl)-prop-2-ynyl ester and 3-chlorophenol.
1HNMR: 7.58 (s, IH), 7.5 (t, IH), 7.43 (m, IH), 7.27 (m, 2H), 7.15 (d, IH), 7.06 d, IH),
4.14 (q, IH), 2.52 (s, 3H), 1.62 (d, 3H)
13C NMR: 159.0, 142.4, 136.5, 136.0, 134.6, 132.8, 131.2, 130.0, 128.2, 124.6, 122.9,
89.5, 83.8, 34.1, 24.7, 21.6.
Example 8
Preparation of 2-|"3-(2.3-Dichloro-phenoxy)-prop-l-ynyll-6-methyl-pyridine
Using method A starting from 2,3-dichlorophenol (0.029g, 0.18mmol) 0.012g, (yield 27%) of the title compound was isolated. M+H: 292.0
Example 9
Preparation of 2-[3-(2,3-Dimethyl-phenoxy)-prop-l-ynyl1-6-methyl-pyridine
Using method A starting from 2,3-dimethylphenol (0.022g, 0.18mmol) 0.01 Og (yield 26%) of the title compound was isolated. M+H: 252.1 Example 10
Preparation of 2-r3-(2,4-Dichloro-phenoxyVprop-l-ynyll-6-methyl-pyridine
Using method A starting from 2,4-dichlorophenol (0.029g, 0.1 δmmol) 0.009g (yield 20%) of the title compound was isolated. M+H: 292.0
Example 11 Preparation of 2-[3-(2,4-Dimethyl-phenoxy)-prop- 1 -ynvπ-6-methyl-pyridine
Using method A starting from 2,4-dimethylphenol (0.022g, 0.18mmol) 0.007g (yield 18%) of the title compound was isolated. M+H: 252.1
Example 12
Preparation of 2-f3-r2,5-Dichloro-phenoxy)-prop-l-ynyl]-6-methyl-pyri dine
Using method A starting from 2,5-dichlorophenol (0.029g, O.lSmmol) 0.024g (yield 54%) of the title compound was isolated. M+H: 292.0 Example 13
Preparation of 2- 3-(2.5-Dimethyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine
Using method A starting from 2,5-dimethylphenol (0.022g, 0.18mmol) 0.017g (yield 45%) of the title compound was isolated. M+H: 252.1
Example 14
Preparation of 2-[3-(2,6-Dimethyl-phenoxy)-prop-l-ynyl1-6-methyl-pyridine
Using method A starting from 2,6-dimethylphenol (0.022g, 0.18mmol) 0.019g (yield 50%) of the title compound was isolated. M+H: 252.1
Example 15 Preparation of 2-Methyl-6- [3-(2-trifluoromethyl-phenoxy)-prop-l -ynyll-pyridine
Using method A starting from 2-trifluoromethylphenol (0.029g, O.lδmmol) 0.015g (yield 35%) of the title compound was isolated. M+H: 292.1
Example 16
Preparation of 2-[3-(2-Benzyloxy-phenoxy -prop-l-ynyl]-6-methyl-pyridine
Using method A starting from benzyl alcohol (0.036g, 0.18mmol) 0.016g (yield 32%) of the title compound was isolated. M+H: 330.2
Example 17
Preparation of 2- 3-(2-Bromo-4, 5-dimethyl-phenoxy) -proρ-l-ynyl]-6-methyl-pyridine
Using method A starting from 2-bromo-4, 5-dimethylphenol (0.036g, 0.18mmol) 0.017g (yield 33%) of the title compound was isolated. M+H: 330.1 Example 18
Preparation of 2-[3-(2-Chloro-4-methoxy-phenoxy)-prop-l -ynyl]-6-methyl-pyridine
Using method A starting from 2-chloro-4-methoxyphenol (0.029g, 0.18mmol) 0.022g (yield 50%) of the title compound was isolated. M+H: 288.1
Example 19 Preparation of 2- 3-(2-Chloro-5-methyl-ρhenoxy)-prop-l-vnyll-6-methyl-pyridine
Using method A starting from 2-chloro-5-methylphenol (0.026g, 0.18mmol) 0.021g (yield 53%) of the title compound was isolated. M+H: 272.1
Example 20
Preparation of 2-[3-(2-Chloro-6-methyl-phenoxy)-prop-l -ynyl"|-6-methyl-pyridine
Using method A starting from 2-chloro-6-methylphenol (0.026g, 0.18mmol) 0.017g (yield 42%) of the title compound was isolated. M+H: 272.1
Example 21
Preparation of 2-Methyl-6- (3-o-tolyloxy-prop-l-ynviypyridine
Using method A starting from 2-methylphenol (0.019g, 0.18mmol) 0.017g (yield 47%) of the title compound was isolated. M+H: 238.1
Example 22
Preparation of 2-Methyl-6- [3-(3A5-trimethyl-phenoxy)-prop-l-vnyl1-pyridine
Using method A starting from 3,4,5-trimethyl phenol (0.025g, 0.18mmol) 0.012g (yield 30%) of the title compound was isolated. M+H: 266.1 Example 23
Preparation of 2- ["3 -(3 ,4-Dichloro-phenoxy)-prop- 1 -ynyll -6-methyl-pyridine
Using method A starting from 3,4-dichloro phenol (0.029g, 0.18mmol) 0.02 lg (yield 49%) of the title compound was isolated. M+H: 292.0
Example 24
Preparation of 2-[3-(3,4-Dimethoxy-phenoxy)-prop-l-ynyll-6-methyl-pyridine
Using method A starting from 3,4-dimethoxy phenol (0.028g, 0.18mmol) 0.017g (yield 39%) of the title compound was isolated. M+H: 284.1
Example 25
Preparation of 2- 3-(3,4-Dimethyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine
Using method A starting from 3,4-dimethyl phenol (0.022g, 0.18mmol) 0.012g (yield 32%) of the title compound was isolated. M+H: 252.1
Example 26
Preparation of 2- 3-f3,5-Dichloro-phenoxy)-prop-l-ynyl]-6-methyl-pyridine
Using method A starting from 3,5-dichlorophenol (0.029g, 0.18mmol) 0.015g (yield 34%) of the title compound was isolated. M+H: 292.0
Example 27
Preparation of 2- [3 -(3 , 5 -Dimethoxy-phenoxy)-prop- 1 - ynyl] -6-methyl-pyridine
Using method A starting from 3,5-dimethoxyphenol (0.028g, 0.18mmol) 0.014g (yield 33%) of the title compound was isolated. M+H: 284.1 Example 28
Preparation of 2- 3-(3.5-Dimethyl-phenoxyVprop-l-vnyll-6-methyl-pyridine
Using method A starting from 3,5-dimethylphenol (0.022g, 0.18mmol) 0.018g (yield 47%) of the title compound was isolated. M+H: 252.1
Example 29 Preparation of 2-|"3-(3-Bromo-phenoxy)-prop-l-vnyl]-6-methyl-pyridine
Using method A starting from 3-bromophenol (0.03 lg, 0.18mmol) 0.020g (yield 45%) of the title compound was isolated. M+H: 302.0
Example 30
Preparation of 3- [3- (6-Methyl-pyridin-2-yl)-prop-2-vnyloxyl-benzonitrile
Using method A starting from 3-hydroxybenzonitrile (0.02 lg, 0.18mmol) 0.0 lOg (yield 27%) of the title compound was isolated. M+H: 249.1
Example 31
Preparation of 2- [3 -(3-Ethyl-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine
Using method A starting from 3-ethylphenol (0.022g, 0.18mmol) 0.030g (yield 79%) of the title compound was isolated. M+H: 252.1
Example 32 Preparation of 2-methyl-6-|"3-(3-methylphenoxy)prop- 1 -yn- 1 -yl"|pyridine
To 3-chlorophenol (0.031 g, 0.24 mmol, 1.2 eq.) in a glass vial was added anhydrous potassium carbonate (0.041 g, 0.30 mmol, 1.5 eq.), followed by 0.5 mL of a 0.4 M solution of 3-(6-methylpyridin-2-yl)prop-2-yn-l-yl methanesulfonate (0.045 g, 0.2 mmol) in acetone. The vial was sealed and heated at 60 °C for 5 h. The material was filtered through Celite and then vacuum centrifuged. Purification was done by reverse phase column chromatography. Yield: 0.023 g (40 %). 1H NMR (500 MHz): 7.53 (t, J = 7.8 Hz, IH), 7.27-7.20 (m, ca. 2H, overlap with CDC13 signal), 7.11 (br d, J = 8.0 Hz, IH), 7.04-7.02 (m, IH), 6.98 (br d, J = 7.8 Hz, IH), 6.92 (br d, J = 8.4 Hz, IH), 4.92 (s, 2H), 2.55 (s, 3H). MS m/z: 258 (M+l)
Example 33
Preparation of 2-|"3-(4-chloro-2-methylphenoxy)prop-l-vn-l-yl1-6-methylpyridine:
Prepared in analogy to example 32, but with 4-chloro-2-methylphenol as starting material. Yield: 0.008 g (20 %).
MS m/z: 272 (M+l)
Example 34
Preparation of 2- [3 -(4-chloro-3 ,5 -dimethylphenoxy)prop- 1 -yn- 1 - yl] -6-methylpyridine :
Prepared in analogy to example 32, but in 0.15 mmol scale and with 4-chloro-3,5- dimethylphenol as starting material. Yield: 0.007 g (16 %).
MS m/z: 286 (M+l)
Example 35
Preparation of 2-r3-(4-chloro-3-methylphenoxy)prop-l-yn-l-yl1-6-methylpyridine:
Prepared in analogy to example 32, but in 0.15 mmol scale and with 4-chloro-3- methylphenol as starting material. Yield: 0.010 g (25 %).
MS m/z: 272 (M+l)
Example 36
Preparation of 2- 3-(4-chlorophenoxy)prop-l-yn-l-yl1-6-methylpyridine:
Prepared in analogy to example 32, but in 0.15 mmol scale and with 4-chlorophenol as starting material. Yield: O.OOδ g (21 %). MS m/z: 25δ (M+l)
Example 37 Preparation of 2- [3 -(4-methoxyphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine :
Prepared in analogy to example 32, but in 0.15 mmol scale and with 4-methoxyphenol as starting material. Yield: 0.004 g (11 %).
MS m/z: 254 (M+l)
Example 3δ Preparation of 2-methyl-6- [3-(4-nitrophenoxy)prop- 1 -yn- 1 -yl]pyridine :
Prepared in analogy to example 32, but in 0.15 mmol scale and with 4-nitrophenol as starting material. Yield: 0.014 g (35 %).
MS m/z: 269 (M+l) Example 39
Preparation of 2-methyl-6-[3-(3-nitrophenoxy)prop-l-vn-l-yl]pyridine:
Prepared in analogy to example 32, but in 0.15 mmol scale and with 3-nitrophenol as starting material. Yield: 0.012 g (30 %).
MS ra/z: 269 (M+l)
Example 40
Preparation of 2-methyl-6-|"3-(3-methylphenoxy prop- 1 -yn- 1 -yl]pyridine:
Prepared in analogy to example 32, but with 3-methylphenol as starting material. Yield: 0.012 (25 %).
1H NMR (500 MHz): 7.52 (t, J = 7.8 Hz, IH), 7.24 (d, J = 7.δ Hz, IH), 7.21-7.16 (m, IH), 7.10 (d, J = 7.δ Hz, IH), 6.δ5-6.79 (m, 3H), 4.91 (s, 2H), 2.55 (s, 3H), 2.34 (s, 3H). MS m/z: 23δ (M+l) Example 41
Preparation of 2-methyl-6-r3-(5,6.7.8-tetrahydronaphthalen-2-yloxy)prop-l-yn-l- yl]pyridine:
Prepared in analogy to example 32, but with 5,6,7,8-tetrahydronaphthalen-2-ol as starting material. Yield: 0.021 g (38 %).
1H NMR (300 MHz): 7.52 (t, J = 7.8 Hz, IH), 7.25 (d, J = ca. 7.8 Hz, IH, overlap with CDC13 signal), 7.10 (d, J = 7.8 Hz, IH), 6.99 (d, J = 8.3 Hz, IH), 6.85-6.70 (m, 2H), 4.88 (s, 2H), 2.78-2.67 (m, 4H), 2.55 (s, 3H), 1.80-1.74 (m, 4H). MS m/z: 278 (M+l)
Example 42
Preparation of 2- |"3-(4-isopropylphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine :
Prepared in analogy to example 32, but with 4-isopropylphenol as starting material. Yield: 0.046 (85 %). 1H NMR (500 MHz): 7.52 (t, J = 7.8 Hz, IH), 7.25 (d, J = ca. 7.7 Hz, IH, overlap with CDC13 signal), 7.16 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 7.8 Hz, IH), 6.96 (d, J = 8.4 Hz, 2H), 4.90 (s, 2H), 2.90-2.83 (m, J = 7.0 Hz, IH), 2.55 (s, 3H), 1.23 (d, J = 7.0 Hz, 6H). MS m/z: 266 (M+l)
Example 43
Preparation of 2-[3-(4-fert-butylphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine:
Prepared in analogy to example 32, but with 4-terz,-butylphenol as starting material. Yield: 0.017 g (30 %).
1H NMR (500 MHz): 7.52 (t, J = 7.8 Hz, IH), 7.32 (br d, J = 8.8 Hz, 2H), 7.25 (m, partly overlap with CDC13 signal, 1H(?)), 7.10 (d, J = 7.8 Hz, IH), 6.96 (br d, J = 8.8 Hz, 2H), 4.90 (s, 2H), 2.55 (s, 3H), 1.30 (s, 9H). MS m/z: 280 (M+l)
Example 44
Preparation of 3-(5-fluoro-6-methylpyridin-2-yl)prop-2-vn-l-ol: 6-Bromo-3-fluoro-2-methylpyridine (0.500 g, 2.63 mmol), propargyl alcohol (0.590 g, 10.5 mmol) and bis(triphenylphosphine)palladium(II) chloride (46 mg, 0.065 mmol) were dissolved in triethylamine (1.0 mL) and finally copper(I) iodide was added. The mixture was slowly heated to 50 °C and left under stirring overnight. Hereafter K2CO3 (1.0 M, 25 mL) was added and the solution was extracted with DCM. The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The resulting crude product was subjected to flash chromatography on silica gel with gradient (heptane/EtOAc 1 :0 to 1 :4), which gave the pure product 0.332 g (76 %).
1H-NMR (400 MHz): 7.22 (d, IH), 7.20 (s, IH), 4.57 (m, IH), 4.47 (m, 2H), 2.43 (d, 3H). 13C-NMR (400 MHz): 158.7, 156.1, 147.6 (d), 137.9 (d), 126.4 (d), 122.9 (d), 88.2, 83.4, 50.9, 17.8.
Example 45
Preparation of 4-(5-fluoro-6-methylpyridin-2-yl)but-3-yn-2-ol: 6-Bromo-3-fluoro-2-methylpyridine (0.500 g, 2.63 mmol), 3-butyn-2-ol (0.738 g, 10.5 mmol) and bis(triphenylphosphine)palladium(II) chloride (46 mg, 0.065 mmol) were dissolved in triethylamine (1.0 mL) and finally copper(I) iodide was added. The mixture was slowly heated to 50 °C and left under stirring overnight and then heated to 70 °C for additionally 2 h. Hereafter K2CO3 (1.0 M, 25 mL) was added and the solution was extracted with DCM. The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The resulting crude product was subjected to flash chromatography on silica gel with gradient (heptane/EtOAc 1 :0 to 1 :4), which gave the pure product 0.447 g (95 %).
1H-NMR (400 MHz): 7.18 (s, IH), 7.16 (s, IH), 4.72 (m, IH), 4.45 (m, IH), 2.41 (d, 3H), 1.47 (d, 3H). 13C-NMR (400 MHz): 158.6, 156.0, 147.5 (d), 138.0 (d), 126.3 (d), 122.9 (d), 91.5, 82.1, 58.2, 24.1, 17.8. Example 46
Preparation of 3 -(5 -fluoro-6-methylpyridin-2- yl)prop-2-yn- 1 -yl methanesulfonate : 3-(5-fluoro-6-methylpyridin-2-yl)prop-2-yn-l-ol (40.0 mg, 0.24 mmol) and diisopropylethylamine (125 mg, 0.97 mmol) were dissolved in DCM (1.0 mL) and mesyl chloride was added dropwise. The mixture was stirred for 2 h at room temperature. The reaction was quenched with water (25 mL) and extracted with DCM. The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The crude material was sufficiently pure (LC-MS) to be used for further synthesis.
Example 47 Preparation of 3 -(5-fluoro-6-methylpyridin-2-yl)- 1 -methylprop-2-yn- 1 -yl methanesulfonate :
4-(5-fluoro-6-methylpyridin-2-yl)but-3-yn-2-ol (43.4 mg, 0.24 mmol) and diisopropylethylamine (125 mg, 0.97 mmol) were dissolved in DCM (1.0 mL) and mesyl chloride (55.4 mg, 0.48 mmol) was added dropwise. The mixture was stirred for 2 h at room temperature. The reaction was quenched with water (25 mL) and extracted with DCM. The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The crude material was sufficiently pure (LC-MS) to be used for further synthesis.
Example 48
Preparation of 6-[3-(3,4-dimethylphenoxy^prop-l-yn-l-yl]-3-fluoro-2-methylpyridine:
3-(5-fluoro-6-methylpyridin-2-yl)prop-2-yn-l-yl methanesulfonate (10.0 mg, 0.041 mmol) and 3,4-dimethylphenol (7.5 mg, 0.061 mmol) were dissolved in acetone/DMF (2:1, 3 mL) and K2CO3 (11.4 mg, 0.082 mmol) was added. The mixture was heated to 60 °C overnight.
Hereafter K2CO3 (1.0 M, 25 mL) was added and the solution was extracted with DCM.
The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The resulting crude product was purified by preparative HPLC (C8 kromasil), which afforded the pure product 2.0 mg (9.0 %).
1H-NMR (400 MHz): 7.26 (m, 2H), 7.04 (d, IH), 6.76 (dd, 2H), 4.δ7 (s, 2H), 2.51 (d, 3H), 2.24 (s, 3H), 2.19 (s, 3H).
Example 49
Preparation of 6-["3-(3,4-dimethylphenoxy)but-l -yn-1 -yll-3-fluoro-2-methylpyridine:
3-(5-fluoro-6-methylpyridin-2-yl)-l-methylprop-2-yn-l-yl methanesulfonate (62.3 mg, 0.242 mmol) and 3,4-dimethylphenol (44.4 mg, 0.363 mmol) were dissolved in acetone/DMF (2:1, 3 mL) and K2CO3 (66.9 mg, 0.4δ4 mmol) was added. The mixture was heated to 60 °C overnight. Hereafter K2CO3 (1.0 M, 25 mL) was added and the solution was extracted with DCM. The organic phases were pooled, dried (Na2SO4), filtrated and evaporated. The resulting crude product was purified by preparative HPLC (C8 kromasil), which afforded the pure product 22.0 mg (32 %).
1H-NMR (400 MHz): 7.22 (m, 2H), 7.03 (d, IH), 6.δ2 (m, 2H), 5.04 (q, IH), 2.50 (d, 3H), 2.23 (s, 3H), 2.19 (s, 3H), 1.71 (d, 3H)
Example 50
Preparation of 4-(6-methylpyridin-2-yl)but-3-yn-2-ol:
2-bromo-6-methylpyridine (0.25δ g, 1.5 mmol) was mixed with but-3-yn-2-ol (0.116 g,
1.65 mmol, 1.1 eq.) and (PPh3)2PdCl2 (0.032 g, 0.045 mmol, 0.03 eq.). At 0 °C triethylamine (0.61 g, 0.δ4 mL, 6.0 mmol, 4.0 eq.) was added. The mixture was stirred at 0
°C for 10 min and Cul (0.006 g, 0.03 mmol, 0.02 eq.) was added. The mixture was allowed to reach room temperature and was finally heated at 60 °C for 4h.
Phosphate buffer (10 mL, 0.2 M, pH 7) was added and the water phase was extracted with
DCM (3x10 mL) by using a phase separator. The combined organic phases were dried with sodium sulphate and evaporated. This gave 0.2δ6 g crude product.
After flash chromatography on Si with pentane/EtOAc fractions (first 1 :1, then 3:2 and finally 1:2) as eluent 0.163 g (Yield: 67 %) pure product was isolated as a yellow oil.
TLC: Rf (pentane/EtOAc 1:1) = 0.20.
1H NMR (300 MHz): 7.40 (t, J = 7.δ Hz, IH), 7.10 (d, J = 7.δ Hz, IH), 6.96 (d, J = 7.δ Hz, IH), 4.90 (b, IH), 4.76 (q, J = 6.8 Hz, IH), 2.43 (s, 3H), 1.49 (d, J = 6.7 Hz, 3H). 13C NMR (75 MHz): 158.2, 141.7, 136.2, 123.9, 122.4, 91.7, 82.3, 57.6, 23.9, 23.8. Example 51
Preparation of Methanesulfonic acid l-methyl-3-(6-methyl-pyridin-2-yl)-prop-2-ynyl ester The compound was prepared according to the method in example 46 using 4-(6- methylpyridin-2-yl)but-3-yn-2-ol as starting material.
MS m/z: 240 (M+l)
Example 52
Preparation of 3 -(6-methylpyridin-2-yl)prop-2- yn- 1 -ol :
To 2-bromo-6-methylpyridine (1.72 g, 0.01 mol) was added (PPh3)2PdCl2 (0.116 g, 0.2 mmol, 0.02 eq.) and Cul (0.063 g, 0.3 mmol, 0.03 eq.) at 0 °C under nitrogen, followed by prop-2-yn-l-ol (2.24 g, 2.33 mL, 0.4 mol, 4.0 eq.) and triethylamine (1.50 mL). The reaction mixture was allowed to reach room temperature and then heated at 60 °C for 3.5 h.
Then the reaction mixture was added to water (10 mL) and the pH was adjusted to 6-7 with
2 M HCl. The water phase was extracted with DCM (3 x 10 mL) and the combined organic phases were dried with sodium sulphate and evaporated. This gave 1.719 g crude product.
1.09δ g hereof was subjected to flash chromatography on silica gel with pentane/EtOAc, first 1:1, then 1:2, finally 1:3, as eluent. This gave 0.57δ g product.
13C NMR (75 MHz): 157.7, 141.1, 136.2, 123.7, 122.3, δδ.4, δ3.0, 49.9, 23.5. Example 53
Preparation of 3 -(6-methylpyridin-2- yl)prop-2-yn- 1 - yl methanesulfonate : 3-(6-methylpyridin-2-yl)prop-2-yn-l-ol (0.300 g, 2.04 mmol) was dissolved in DCM (10 mL) under nitrogen over 5-10 min. The solution was cooled to -20 °C (cooling bath: acetone + pieces of dry ice). Triethylamine (0.268 g, 0.37 mL, 0.27 mmol, 1.30 eq.) was added. Methanesulfonyl chloride (0.280 g, 0.19 mL, 0.24 mmol, 1.2 eq.) in DCM (1.5 mL) was added over 3 min. The reaction mixture was stirred at -18 to -22 °C for lh after which time LC/MS only showed product. Water (10 mL) was added. The organic phase was separated and the water phase was extracted with DCM (3 x 10 mL). The organic phases were pooled, dried with magnesium sulphate and evaporated. This gave 0.450 g (yield: 9δ %) as a yellow oil.
1H NMR (300 MHz): 7.61 (t, J = 7.7 Hz, IH), 7.31 (d, J =7.7 Hz,lH), 7.19 (d, J = 7.7 Hz, IH), 5.10 (s, 2H), 3.18 (s, 3H), 2.58 (s, 3H).
13C NMR (75 MHz): 158.9, 140.2, 136.8, 124.5, 123.8, 87.8, 80.7, 57.7, 38.9, 24.2.
Biological evaluation
Functional assessment of mGluR5 antagonism in cell lines expressing mGluR5d
The properties of the compounds of the invention can be analyzed using standard assays for pharmacological activity. Examples of glutamate receptor assays are well known in the art as described in for example Aramori et al, Neuron 8:151 (1992), Tanabe et al., Neuron δ:169 (1992), Miller et al, J Neuroscience 15: 6103 (1995), Balazs, et al, J.
Neurochemistry 69:151 (1997). The methodology described in these publications is incorporated herein by reference. Conveniently, the compounds of the invention can be studied by means of an assay (FLIPR) that measures the mobilization of intracellular calcium, [Ca2+]j in cells expressing mGluR5 or another assay (IP3) that measures inositol phosphate turnover.
FLIPR Assay Cells expressing human mGluR5d as described in WO97/05252 are seeded at a density of 100,000 cells per well on collagen coated clear bottom 96-well plates with black sides and experiments are done 24 h following seeding. All assays are done in a buffer containing 127 mM NaCl, 5 mM KC1, 2 mM MgCl2, 0.7 mM NaH2PO4, 2 mM CaCl2, 0.422 mg/ml NaHCO3, 2.4 mg/ml HEPES, 1.8 mg/ml glucose and 1 mg/ml BSA Fraction IV (pH 7.4). Cell cultures in the 96-well plates are loaded for 60 minutes in the above mentioned buffer containing 4 μM of the acetoxymethyl ester form of the fluorescent calcium indicator fluo- 3 (Molecular Probes, Eugene, Oregon) in 0.01% pluronic acid (a proprietary, non-ionic surfactant polyol - CAS Number 9003-11-6). Following the loading period the fluo-3 buffer is removed and replaced with fresh assay buffer. FLIPR experiments are done using a laser setting of O.δOO W and a 0.4 second CCD camera shutter speed with excitation and emission wavelengths of 4δδ nm and 562 nm, respectively. Each experiment is initiated with 160 μl of buffer present in each well of the cell plate. A 40 μl addition from the antagonist plate was followed by a 50 μL addition from the agonist plate. A 90 second interval separates the antagonist and agonist additions. The fluorescence signal is sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals immediately after each of the two additions. Responses are measured as the difference between the peak height of the response to agonist, less the background fluorescence within the sample period. IC50 determinations are made using a linear least squares fitting program.
IP 3 Assay
An additional functional assay for mGluR5d is described in WO97/05252 and is based on phosphatidylinositol turnover. Receptor activation stimulates phospholipase C activity and leads to increased formation of inositol l,4,5,triphosphate (IP3). GHEK stably expressing the human mGluR5d are seeded onto 24 well poly-L-lysine coated plates at 40 x 104 cells /well in media containing 1 μCi/well [3H] myo-inositol. Cells were incubated overnight (16 h), then washed three times and incubated for 1 h at 37°C in HEPES buffered saline (146 mM NaCl, 4.2 mM KC1, 0.5 mM MgCl2, 0.1% glucose, 20 mM HEPES, pH 7.4) supplemented with 1 unit ml glutamate pyruvate transaminase and 2 mM pyruvate. Cells are washed once in HEPES buffered saline and pre-incubated for 10 min in HEPES buffered saline containing 10 mM LiCl. Compounds are incubated in duplicate at 37°C for 15 min, then either glutamate (δO μM) or DHPG (30 μM) is added and incubated for an additional 30 min. The reaction is terminated by the addition of 0.5 ml perchloric acid (5%) on ice, with incubation at 4°C for at least 30 min. Samples are collected in 15 ml polyproplylene tubes and inositol phosphates are separated using ion-exchange resin (Dowex AGl-Xδ formate form, 200-400 mesh, BIORAD) columns. Inositol phosphate separation was done by first eluting glycero phosphatidyl inositol with δ ml 30 mM ammonium formate. Next, total inositol phosphates is eluted with δ ml 700 mM ammonium formate / 100 mM formic acid and collected in scintillation vials. This eluate is then mixed with δ ml of scintillant and [3H] inositol incorporation is determined by scintillation counting. The dpm counts from the duplicate samples are plotted and IC50 determinations are generated using a linear least squares fitting program.
Abbreviations BSA Bovine Serum Albumin
CCD Charge Coupled Device
CRC Concentration Response Curve
DHPG 3 ,5-dihydroxyphenylglycine
DPM Disintegrations per Minute EDTA Ethylene Diamine Tetraacetic Acid
FLIPR Fluorometric Imaging Plate reader
GHEK GLAST-containing Human Embrionic Kidney
GLAST glutamate/aspartate transporter
HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid (buffer) IP3 inositol triphosphate Generally, the compounds are active in the assay above with IC50 values less than 10 000 nM. In one aspect of the invention, the IC5o value is less than 1 μM. In a further aspect of the invention, the IC50 value is less than 100 nM.
Examples of ICSQ values for individual compounds is given below:
Screening for compounds active against TLESR
Adult Labrador retrievers of both genders, trained to stand in a Pavlov sling, are used. Mucosa-to-skin esophagostomies are formed and the dogs are allowed to recover completely before any experiments are done.
Motility measurement
In brief, after fasting for approximately 17 h with free supply of water, a multilumen sleeve/sidehole assembly (Dentsleeve, Adelaide, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures. The assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Adelaide, South Australia). An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.
When a baseline measurement free from fasting gastric/LES phase III motor activity has been obtained, placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein. Ten min after i.v. administration, a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg. The infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until an intragastric pressure of 10+1 mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs.
TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s. The relaxation should not be preceded by a pharyngeal signal 2s before its onset in which case the relaxation is classified as swallow- induced. The pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.

Claims

Claims
1. A compound of formula I
wherein R1 is selected from hydrogen, Ci-04 alkyl, C3-C6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C1-C4 alkyl; R2 is selected from hydrogen and C1-C4 alkyl; R3 is selected from hydrogen, C1-C4 alkyl, F, CF3, CHF2 and CH2F; R4 is selected from hydrogen, F, CF3, CHF2, CH2F and CH3; R5 is selected from hydrogen and F; R6 is selected from hydrogen and F; Y1 is selected from hydrogen; halogen; nitrile; CΪ-C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; benzyloxy; nitro in the meta or para position; and C!-C4 alkyl ester; Y2 is selected from hydrogen; halogen; nitrile; C C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and C1-C4 alkyl ester; Y3 is selected from hydrogen; halogen; nitrile; C1-C4 alkoxy; C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom; and -C4 alkyl ester; or Y and Y may form an aromatic or non-aromatic ring, optionally substituted by halogen, nitrile, Cχ-C alkoxy, C1-C4 alkyl wherein one or more of the hydrogen atoms of the alkyl group may be substituted for a fluorine atom, benzyloxy or C1-C4 alkyl ester; with the proviso that when Yl is hydrogen, Y2 is selected from halogen, nitrile, - C4 alkoxy, and C1-C4 alkyl; as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.
2. A compound of formula I
wherein R1 is selected from hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by C1-C4 alkyl; R is selected from hydrogen and C1-C4 alkyl; R3 is selected from hydrogen, C1-C4 alkyl, F, CF3, CHF2 and CH2F; R4 is selected from hydrogen, F, CF3, CHF2, CH2F and CH3; R5 is selected from hydrogen and F; R6 is selected from hydrogen and F; Y1 is selected from hydrogen, halogen, nitrile, C1-C4 alkoxy, and C1-C4 alkyl; Y is selected from hydrogen, halogen, nitrile, C]-C4 alkoxy, and CJ-C4 alkyl; Y3 is selected from hydrogen, halogen, nitrile, C1-C4 alkoxy, and C1-C4 alkyl; with the proviso that when Y1 is hydrogen, Y2 is selected from halogen, nitrile, Ci- C4 alkoxy, and C1-C4 alkyl; as well as pharmaceutically acceptable salts, hydrates, isoforms and/or optical isomers thereof.
3. A compound according to formula I of claim 1 or 2, wherein R1 is hydrogen or C C3 alkyl; R2 is hydrogen; R3 is selected from hydrogen and Cι-C2 alkyl; R4 is hydrogen; R5 is hydrogen; R6 is hydrogen; Y1 is selected from hydrogen, chloro, C1-C2 alkoxy, and Cι-C2 alkyl; and Y is selected from hydrogen, chloro, CpC2 alkoxy, and -C2 alkyl; with the proviso that when Y is hydrogen, Y is selected from chloro, C1-C2 alkoxy, and C1-C2 alkyl; and Y3 is hydrogen.
4. A compound according to claim 1 selected from; 2-[3-(3-methoxyphenoxy)prop-l-yn-l-yl]-6-methylpyridine; 2- [3 -(3 -methoxyphenoxy)prop- 1 -yn- 1 -yl]pyridine; 2-[3-(3-chlorophenoxy)but- 1 -yn- 1 -yl]-6-methylpyridine; 2-Methyl-6- (3-p-tolyloxy-prop-l -ynyl)-pyridine; 2- [3 -(2,3 -Dichloro-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine ; 2-[3-(2,3-Dimethyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine; 2-[3-(2,3-Dimethyl-phenoxy)-prop- 1 -ynyl]-6-methyl-pyridine; 2-[3-(2,4-Dichloro-phenoxy)-prop-l -ynyl]-6-methyl-pyridine; 2- [3 -(2,4-Dimethyl-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine; 2-[3-(2,5-Dichloro-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine; 2- [3 -(2, 5 -Dirnethyl-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine; 2-[3-(2,6-Dimethyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine; 2-Methyl-6- [3 -(2-trifluoromethyl-phenoxy)-proρ- 1 -ynyl] -pyridine; -[3-(2-Benzyloxy-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(2-Bromo-4, 5-dimethyl-phenoxy) -prop- 1 -ynyl] -6-methyl-pyridine;-[3-(2-Chloro-4-methoxy-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(2-Chloro-5-methyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(2-Chloro-6-methyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-Methyl-6- (3 -o-tolyloxy-prop- 1 -ynyl)-pyridine;-Methyl-6- [3-(3,4,5-trimethyl-phenoxy)-prop-l-ynyl]-pyridine;-[3-(3,4-Dichloro-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(3,4-Dimethoxy-phenoxy)-prop- 1 -ynyl]-6-methyl-pyridine;-[3-(3,4-Dimethyl-phenoxy)-prop-l -ynyl] -6-methyl-pyridine;-[3-(3,5-Dichloro-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(3,5-Dimethoxy-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;-[3-(3,5-Dimethyl-phenoxy)-prop-l-ynyl]-6-methyl-pyridine;- [3 -(3 -Bromo-phenoxy)-prop- 1 -ynyl] -6-methyl-pyridine ;- [3- (6-Methyl-pyridin-2-yl)-prop-2-ynyloxy]-benzonitrile;- [3 -(3 -Ethyl-phenoxy)-ρrop- 1 -ynyl] -6-methyl-pyridine ;-methyl-6-[3-(3-methylphenoxy)prop- 1 -yn- 1 -yl]pyridine;-[3-(4-chloro-2-methylphenoxy)prop-l-yn-l-yl]-6-methylpyridine;-[3-(4-chloro-3,5-dimethylphenoxy)prop-l-yn-l-yl]-6-methylpyridine;- [3 -(4-chloro-3 -methylphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine ;-[3-(4-chlorophenoxy)prop- 1 -yn- 1 -yl]-6-methylpyridine;- [3 -(4-methoxyphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine;-methyl-6-[3-(4-nitrophenoxy)prop-l-yn-l-yl]pyridine;-methyl-6- [3 -(3 -nitrophenoxy)prop- 1 -yn- 1 -yl]pyridine ;-methyl-6-[3-(3-methylphenoxy)prop-l-yn-l-yl]pyridine;-methyl-6-[3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)prop- 1 -yn- 1 -yljpyridine;- [3 -(4-isopropylphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine;- [3 -(4-tβrt-butylphenoxy)prop- 1 -yn- 1 -yl] -6-methylpyridine;-[3-(3,4-dimethylphenoxy)prop-l-yn-l-yl]-3-fluoro-2-methylpyridine; and-[3-(3,4-dimethylphenoxy)but-l-yn-l-yl]-3-fluoro-2-methylpyridine.
5. A compound according to any one of claims 1-4 for use in therapy.
6. A compound according to claim 5, wherein the therapy is treatment or prevention of gastroesophageal reflux disease.
7. Use of a compound according to formula I of claim 1 or 2, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations.
8. Use of a compound according to formula I of claim 1 or 2, or a pharmaceutically acceptable salt or an optical isomer thereof, for the manufacture of a medicament for treatment or prevention of gastroesophageal reflux disease.
9. A pharmaceutical composition comprising a compound of formula I of claim 1 or 2 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.
10. A process for the preparation of a compound of formula I, whereby a coupling reaction of the aryl bromide A
A and the alcohol B
B is performed in the presence of a base such as triethyl amine to give the alcohol C whi h is then converted into the mesylate D
and reacted with an alcohol, and wherein R1 is selected from hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, aryl and heteroaryl, wherein the aryl or heteroaryl may be substituted by d-C4 alkyl; R2 is selected from hydrogen and C]-C4 alkyl; R3 is selected from hydrogen, C1-C4 alkyl, F, CF3, CHF2 and CH2F; R4 is selected from hydrogen, F, CF3, CHF2, CH2F and CH3; R5 is selected from hydrogen and F; R6 is selected from hydrogen and F.
11. A compound selected from 3-(5-fluoro-6-methylpyridin-2-yl)prop-2-yn-l-ol; 4-(5- fluoro-6-methylpyridin-2-yl)but-3-yn-2-ol; 3-(5-fluoro-6-methylpyridin-2-yl)prop- 2-yn- 1 -yl methanesulfonate; 3-(5-fluoro-6-methylpyridin-2-yl)- 1 -methylprop-2-yn- 1-yl methanesulfonate; 4-(6-methylpyridin-2-yl)but-3-yn-2-ol; and Methanesulfonic acid l-methyl-3-(6-methyl-pyridin-2-yl)-prop-2-ynyl ester.
12. A method for the inhibition of transient lower esophageal sphincter relaxations whereby an effective amount of a compound of formula I of claim 1 or 2 is administered to a subject in need of such inhibition.
13. A method for the treatment or prevention of gastroesophageal reflux disease, whereby an effective amount of a compound of formula I of claim 1 or 2 is administered to a subject in need of such treatment or prevention.
EP04795637A 2003-10-31 2004-10-20 Alkynes iii Withdrawn EP1677788A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56075403P 2003-10-31 2003-10-31
PCT/US2004/034501 WO2005044265A1 (en) 2003-10-31 2004-10-20 Alkynes iii

Publications (1)

Publication Number Publication Date
EP1677788A1 true EP1677788A1 (en) 2006-07-12

Family

ID=34573078

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04795637A Withdrawn EP1677788A1 (en) 2003-10-31 2004-10-20 Alkynes iii

Country Status (5)

Country Link
EP (1) EP1677788A1 (en)
JP (1) JP2007509934A (en)
CN (1) CN1871001A (en)
CA (1) CA2549965A1 (en)
WO (1) WO2005044265A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
JP2010502664A (en) 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
WO2008113835A1 (en) * 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
MX2010014222A (en) 2008-06-30 2011-03-29 Novartis Ag Star Combinations comprising mglur modulators for the treatment of parkinson's disease.
EP2959902A1 (en) 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (en) 2009-09-22 2018-09-16 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
AU2011268865A1 (en) 2010-06-24 2013-01-31 Novartis Ag Use of 1H-quinazoline-2,4-diones
WO2012101060A1 (en) 2011-01-27 2012-08-02 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
MX2014002693A (en) 2011-09-07 2014-06-04 Novartis Ag Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy.
MX362819B (en) 2013-01-15 2019-02-18 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy.
KR101879919B1 (en) 2013-01-15 2018-07-18 노파르티스 아게 Use of alpha 7 nicotinic acetylcholine receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
JP4815083B2 (en) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション Heterocyclic compounds and methods of use thereof
CN1468055A (en) * 2000-10-03 2004-01-14 �����ɷ� Phenylpropynylhydroxypyridine herbicide
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
AR035087A1 (en) * 2001-08-09 2004-04-14 Syngenta Participations Ag PIRIDIL-ALQUINOS AND PIRIDIL-N-OXIDO-ACTIVE HERBICIDE ALKINES, PROCEDURE FOR PREPARATION, HERBICIDE COMPOSITION AND TO INHIBIT THE GROWTH OF PLANTS, METHOD FOR CONTROLLING GROWTH OF INDESEABLE PLANTS, AND METHOD OF CREAM INHIBITION
US20040116462A1 (en) * 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005044265A1 *

Also Published As

Publication number Publication date
CA2549965A1 (en) 2005-05-19
WO2005044265A1 (en) 2005-05-19
JP2007509934A (en) 2007-04-19
CN1871001A (en) 2006-11-29

Similar Documents

Publication Publication Date Title
WO2005044265A1 (en) Alkynes iii
US8563583B2 (en) Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
EP2119705A1 (en) 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
EP1677789A1 (en) Alkynes i
JP7278273B2 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinases
CA2671943A1 (en) Compounds having both angiotensin ii receptor antagonism and ppary activating activities
JP2007525513A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005044267A1 (en) Alkynes ii
Wang et al. Design, synthesis and anti-inflammatory evaluation of novel 5-benzylidene-3, 4-dihalo-furan-2-one derivatives
WO2008025526A1 (en) Indole derivatives, their manufacture and use as pharmaceutical agents
EP1713791B1 (en) 5-fluoro- and chloro-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5
KR100849352B1 (en) Benzo-fused Compounds as PPA Activators
EP0757988A1 (en) Imidazole derivative and process for producing the same
JP2650786B2 (en) Disubstituted polycyclic compounds as cognitive enhancers
US20150175545A1 (en) Preparation Method of Fluoro-Substituted Deuterated Diphenylurea
US9550753B2 (en) Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
WO2005082884A2 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease
US7179812B2 (en) Diazine derivatives
US7030145B2 (en) Pyridinyl derivatives for the treatment of depression
TWI828783B (en) Biaryl derivative and use thereof
HK1095598B (en) 5-fluoro-and chloro-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5
CZ2001993A3 (en) 2,3-Disubstituted pyridine derivative, process of its preparation, pharmaceutical preparation in which it is comprised and intermediate thereof
HK1189232B (en) Novel phenylpyridine derivative and drug containing same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060428

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1092719

Country of ref document: HK

17Q First examination report despatched

Effective date: 20070314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070725

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1092719

Country of ref document: HK